- Home
- CANG vs CAPR Comparison
CANG vs CAPR Comparison
Compare CANG & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- CAPR
- Stock Information
- Founded
- CANG 2010
- CAPR 2005
- Country
- CANG China
- CAPR United States
- Employees
- CANG N/A
- CAPR N/A
- Industry
- CANG Computer Software: Prepackaged Software
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CANG Technology
- CAPR Health Care
- Exchange
- CANG Nasdaq
- CAPR Nasdaq
- Market Cap
- CANG 462.1M
- CAPR 453.9M
- IPO Year
- CANG 2018
- CAPR N/A
- Fundamental
- Price
- CANG $5.24
- CAPR $10.25
- Analyst Decision
- CANG
- CAPR Strong Buy
- Analyst Count
- CANG 0
- CAPR 8
- Target Price
- CANG N/A
- CAPR $33.75
- AVG Volume (30 Days)
- CANG 440.1K
- CAPR 3.2M
- Earning Date
- CANG 08-28-2025
- CAPR 08-06-2025
- Dividend Yield
- CANG N/A
- CAPR N/A
- EPS Growth
- CANG N/A
- CAPR N/A
- EPS
- CANG 0.00
- CAPR N/A
- Revenue
- CANG $247,219,627.00
- CAPR $17,363,588.00
- Revenue This Year
- CANG $431.64
- CAPR $258.96
- Revenue Next Year
- CANG $23.36
- CAPR $8.02
- P/E Ratio
- CANG $2,769.28
- CAPR N/A
- Revenue Growth
- CANG 46.60
- CAPR N/A
- 52 Week Low
- CANG $1.40
- CAPR $3.52
- 52 Week High
- CANG $9.66
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- CANG 62.58
- CAPR 47.85
- Support Level
- CANG $4.26
- CAPR $9.45
- Resistance Level
- CANG $4.62
- CAPR $11.58
- Average True Range (ATR)
- CANG 0.29
- CAPR 1.44
- MACD
- CANG 0.05
- CAPR -0.14
- Stochastic Oscillator
- CANG 92.68
- CAPR 54.08
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and related businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives majority of its revenue from the bitcoin mining business.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.